[Perilymphatic injection of interleukin-2 (IL-2) in recurrent squamous cell carcinoma of the head and neck].
Twenty patients with recurrent squamous cell carcinoma of the head and neck received daily injections of interleukin-2 (IL-2) from the Jurkat T-cell line, purified by high pressure liquid chromatography for 10 days. Two hundred (ten patients), one thousand (five patients) and five thousand (five patients) units of IL-2 in 0.5 ml were injected 1.5 cm from the point where the sternocleidomastoid muscle inserts itself on the mastoid. Whenever possible, the treatment cycles were repeated at 45 day intervals. In 13 patients with contralateral or bilateral cervical lymph nodes, complete or partial disappearance of the tumor was observed. There were non systemic disturbances after injection and only moderate local swelling and pain.
Cortesina
G
G
De Stefani
A
A
Giovarelli
M
M
Barioglio
M G
MG
Cavallo
G P
GP
Galeazzi
E
E
Jemma
C
C
Forni
G
G
D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007273:Injections, Intramuscular; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000627:therapeutic use; D008198:Lymph Nodes; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*
D007376:Interleukin-2
Iniezione perilinfatica di interleuchina-2 (IL-2) in recidive di carcinomi a cellule squamose della testa e del collo.